#873USNYSE

EW

Edwards Lifesciences

$89.78USD

Data as of 2026-09-05

Composite Score48.2Average

≤−99

Margin of safety−121%Expensive

Fair value$40.56

Target$58.15

Loss chance61%Moderate-high

SizeLarge cap

SectorHealth Care

Dividend—

TypeCommon stock

Price

Pillar breakdown

0–100 percentile rank against the current universe (sector-relative for Quality / Value / Growth / Profitability)

Health Care median (n=163)

Quality
Profit margins & asset efficiency
56
Strong
Health Care median (n=163) 51
Value
Price vs fundamentals
20
Poor
Health Care median (n=163) 51
Growth
Revenue & earnings trajectory
36
Weak
Health Care median (n=163) 50
Momentum
Recent price strength
49
Average
Health Care median (n=163) 62
Health
Balance sheet & solvency
82
Exceptional
Health Care median (n=163) 56
Profitability
ROE, ROA, ROIC
68
Strong
Health Care median (n=163) 49
Technical
Trend & volatility signals
64
Strong
Health Care median (n=163) 62
Risk
Volatility & drawdown profile
54
Average
Health Care median (n=163) 47

025405570100

Exceptional (70+)Strong (55–70)Average (40–55)Weak (25–40)Poor (<25)

Pillars not shown: Sentiment, ML (Phase 5+).

Risk Summary

Low

Manipulation index

5/100

Composite penalty: −0.50 pts (informational; rank uses raw composite)

Fired components (1)

Insider sell cluster (Cohen-Malloy-Pomorski 2012)[insider_sell_cluster]

Rolls up Phase 4.5 earnings-manipulation defenses (Sloan · Beneish · Dechow · REM · restatement · late-filing · earnings- quality time-series) into a single 0-100 risk index. The soft composite penalty (max 10 pts) is informational only — the ranking uses the raw composite score per project Rule 16.

Fair price check

6 different valuation methods each estimate what EW should be worth, then we compare to today's price.

Heavily overvalued

Models suggest EW is far above estimated fair value

Today's price

$89.78

Median fair price

$40.56

-55% vs today's price

Of 6 methods:6 say pricey

EV/EBITDAOvervalued
thinks it's expensive — estimates $58.15, about 35% below today
P/B multiplesOvervalued
thinks it's expensive — estimates $56.53, about 37% below today
P/E multiplesOvervalued
thinks it's expensive — estimates $48.69, about 46% below today
Graham (defensive)Overvalued
thinks it's expensive — estimates $32.44, about 64% below today
DCF (2-stage)Overvalued
thinks it's expensive — estimates $25.84, about 71% below today
Residual IncomeOvervalued
thinks it's expensive — estimates $22.86, about 75% below today

How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.

Fair price ensemble

Median fair: $40.56
Margin of safety(vs fair value): < −99%
Max (ex-outliers): $58.15
Tangible BVPS: $12.64

Insider-sell cluster

Median of all applicable methods (current price $89.78). Per-method estimates + each method’s cheap/fair/pricey read are in the Fair price check above. Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.

Defense layer. Flags mark elevated risk, never confirmed fraud. This model cannot catch every manipulation and decays after publication — weigh it against its stated error rates.

Supporting dataRaw fundamentals & data-quality provenance behind the scores above

Raw fundamentals (SEC EDGAR)

Metric	Value
Market cap	$51.75B
Revenue (TTM)	$6.51B
Net income (TTM)	$1.00B
Operating cash flow (TTM)	$1.72B
CapEx (TTM)	$286.70M
Free cash flow (TTM)CFO − CapEx	$1.43B
Total assets	$13.87B
Total liabilities	$3.14B
Stockholders' equity	$10.62B
Cash & equivalents	$2.91B
Shares outstanding	576.40M
EPS (basic)	$1.74
EPS (diluted)	$1.74
P/E ratio (TTM)	51.50

TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).

Data quality

Latest filed date: 2026-08-04
Latest period end: 2026-07-31
Filing lag: 32 days
Missing metrics: 2(interest_expense, dividends_paid)